Why developing the world’s first malaria vaccine has taken so long
The jab is expected to save tens of thousands of children’s lives each year
ON JULY 5TH the World Health Organisation, UNICEF and Gavi, an organisation promoting vaccination, announced that 12 African countries would receive 18m doses of the world’s first malaria vaccine. Mosquirix, developed by GSK, a British pharma firm, will be deployed over two years with deliveries starting at the end of 2023. It is expected to save tens of thousands of lives each year, mostly of very young children. Around 95% of malaria cases and deaths are in Africa, and at least 28 countries there have expressed an interest in the new jab; by 2026 demand is expected to reach 40m-60m doses. Why has it taken so long to develop a malaria vaccine?
From the July 22nd 2023 edition
Discover stories from this section and more in the list of contents
Explore the editionMore from The Economist explains
What do Greenlanders think of being bought?
Donald Trump’s desire for Greenland, and a shabby visit by his son, reignite the independence debate
What would Donald Trump gain from seizing the Panama Canal?
The president-elect claims the crossing is controlled by China and rips off American consumers
Where does Santa come from?
How a miracle-working Greek bishop, Dutch folk figure and early New York icon became the ubiquitous symbol of Christmas
Who are the main rebel groups in Syria?
They were united against the country’s dictator. Now they have little in common
Is RFK junior right to say America allows more toxins than the EU?
He is, but things are slowly beginning to change
What would it cost to kill coal?
The price of shutting down coal power, and what would be gained